Servier's $1.55 billion muscular dystrophy drug fails first major test
The setback affects a form of Becker muscular dystrophy that currently lacks treatment options.
Read at STAT →Full coverage · 5 outlets
- STAT · lead
- MedCity NewsServier Stumbles in Muscle Disease as Drug From $1.5B Deal Fails Pivotal Test
- European Biotechnology MagazineServier’s $1.55B Edgewise acquisition backfires after Phase 2 setback
- Yahoo FinanceServier’s $1.55bn muscular dystrophy drug fails Phase III BMD trial
- SeekingalphaEdgewise Therapeutics: The Servier Deal Creates A Self-Funded Cardiovascular Platform